Mediwelcome Healthcare Management & Technology Inc (2159) Fair Value & Analysis
Healthcare · HK · Market cap HK$440M
Fair value as of: Aug 13, 2026
From 25 valuation models · updated 3 days ago
Share price +12.3% over the past month.
A solid business, but screening 72% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.6120). The favourable scenario is already priced in.
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.3050 – HK$2.95 · fair‑value band HK$0.3910 – HK$0.6120 · the HK$1.73 price screens above the HK$0.4845 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Mediwelcome Healthcare Management & Technology Inc (2159) currently trades at HK$1.73, while our model-based Fair Value estimate is HK$0.4845, implying the stock looks roughly 72.0% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Mediwelcome Healthcare Management & Technology Inc generated revenue of HK$468M at a net margin of 2.1%. Revenue grew 88.5% year over year. It earns a return on equity of 7.8%. The balance sheet holds a net cash position of HK$44.9M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.3910 (bear case) to HK$0.6120 (bull case); at HK$1.73, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 24% below its 52-week high and 204% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -72%, 2159 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (HK$0.7200) versus Earnings-Based (HK$0.2500). Highest evidence: Residual Income (76).
Notify me when 2159 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 55
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Mediwelcome Healthcare Management & Technology Inc., an investment holding company, provides integrated healthcare marketing solutions in the People's Republic of China.
Full company description
Mediwelcome Healthcare Management & Technology Inc., an investment holding company, provides integrated healthcare marketing solutions in the People's Republic of China. The company offers academic conference management system, a digital management system for medical conference; scientific data reporting system, a technical service of single disease clinical research data collection; Medical Media, an official WeChat of tiantan international cerebrovascular disease conference; and health education media, a health science cloud platform, patient care center, patient management center, and health education media. It also provides medical conference, patient education and screening, and marketing strategy and consulting services; digital marketing and sales solutions services; contract research organization services; and internet hospital services. In addition, the company offers digital therapy services; science research and development services; and IT and software services. The company was founded in 2000 and is headquartered in Beijing, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Mediwelcome Healthcare Management & Technology Inc reported revenue of HK$468M in FY2025 versus HK$708M in FY2021, a compound −9.8%/yr. Reported net income was HK$10.0M in FY2025, compounding +21.1%/yr from FY2021.
2159 screens 72% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 125 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $241.51 | $91.49 | -62% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $105.50 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $58.48 | $17.18 | -71% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.99 | $25.91 | +4% |
| Privia Health Group PRVA | $21.54 | $5.26 | -76% |
Compare Mediwelcome Healthcare Management & Technology Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Mediwelcome Healthcare Management & Technology Inc (2159) overvalued or undervalued?
What is the fair value of 2159?
What is the quality score of 2159?
What is the revenue of Mediwelcome Healthcare Management & Technology Inc (2159)?
What is the net profit margin of 2159?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Mediwelcome Healthcare Management & Technology Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.